Breaking Finance News

A statement released earlier today by Maxim Group about Bluebirdbio (NASDAQ:BLUE) raises the target price to $87.00

Bluebirdbio (NASDAQ:BLUE) had its target price raised to $87.00 by Maxim Group in a report released Thursday December 01, 2016. The raised price target implies a potential upside of 0.44% from the company's most recent stock price close.

On 3/01/2016, BTIG Research released a statement for Bluebirdbio (NASDAQ:BLUE) bumped up the target price from $0.00 to $72.00 that suggested an upside of 0.56%.

Boasting a price of $60.35, Bluebirdbio (NASDAQ:BLUE) traded 17.40% higher on the day. The last stock close price is up 33.57% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Bluebirdbio has recorded a 50-day moving average of $55.97 and a 200-day moving average of $53.04. 4,814,204 shares of Bluebirdbio traded, up from an avg. volume of 1,371,750

Performance Chart

Bluebirdbio (NASDAQ:BLUE)

With a total market value of $0, Bluebirdbio has with a one year low of $35.37 and a one year high of $94.61 .

A total of 14 analysts have released a report on Bluebirdbio. Six brokerages rating the company a strong buy, six brokerages rating the company a buy, three brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $89.07.

General Company Details For Bluebirdbio (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.